The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy
Open accessAbstract
More than 90% of ovarian cancers have been thought to arise from epithelial cells that cover the ovarian surface or, more frequently, line subserosal cysts. Recent studies suggest that histologically similar cancers can arise from the fimbriae of Fallopian tubes and from deposits of endometriosis. Different histotypes are observed that resemble epithelial cells from the normal Fallopian tube (serous), endometrium (endometrioid), cervical glands (mucinous), and vaginal rests (clear cell) and that share expression of relevant HOX genes which drive normal gynecological differentiation. Two groups of epithelial ovarian cancers have been distinguished: type I low-grade cancers that present in early stage, grow slowly, and resist conventional chemotherapy but may respond to hormonal manipulation; and type II high-grade cancers that are generally diagnosed in advanced stage and grow aggressively but respond to chemotherapy. Type I cancers have wild-type p53 and BRCA1/2, but have frequent mutations of Ras and Raf as well as expression of IGFR and activation of the phosphatidylinositol-3-kinase (PI3K) pathway. Virtually all type II cancers have mutations of p53, and almost half have mutation or dysfunction of BRCA1/2, but other mutations are rare, and oncogenesis appears to be driven by amplification of several growth-regulatory genes that activate the Ras/MAPK and PI3K pathways. Cytoreductive surgery and combination chemotherapy with platinum compounds and taxanes have improved 5-yr survival, but less than 40% of all stages can be cured. Novel therapies are being developed that target high-grade serous cancer cells with PI3Kness or BRCAness as well as the tumor vasculature. Both in silico and animal models are needed that more closely resemble type I and type II cancers to facilitate the identification of novel targets and to predict response to combinations of new agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote, I., Tropé, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, A. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,537
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
Bast, R. C., Klug, T. L., John, E. S., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker, L., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198310133091503 · Cited by 2,135
Self-citationARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. C., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3144 · Cited by 1,464
Self-citationThe biology of ovarian cancer: new opportunities for translation
Bast, R. C., Hennessy, B., & Mills, G. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2644 · Cited by 1,358
Self-citationAlberts, D. S., Liu, P. Y., Hannigan, E. V., O'Toole, R., Williams, S. D., Young, J. A., Franklin, E. W., Clarke-Pearson, D. L., Malviya, V. K., DuBeshter, B., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352603 · Cited by 1,228
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Jones, S., Wang, T.-L., Shih, I.-M., Mao, T.-L., Nakayama, K., Roden, R., Glas, R., Slamon, D., Diaz, L. A., Vogelstein, B., et al. (2010) · Science · doi:10.1126/science.1196333 · Cited by 1,219
Shih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
Ovarian cancer: strategies for overcoming resistance to chemotherapy
Agarwal, R., & Kaye, S. B. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1123 · Cited by 1,154
Markman, M., Bundy, B. N., Alberts, D. S., Fowler, J. M., Clark-Pearson, D. L., Carson, L. F., Wadler, S., & Sickel, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1001 · Cited by 1,080
JACOBS, I., ORAM, D., FAIRBANKS, J., TURNER, J., FROST, C., & GRUDZINSKAS, J. G. (1990) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1990.tb02448.x · Cited by 962
A candidate precursor to serous carcinoma that originates in the distal fallopian tube
Lee, Y., Miron, A., Drapkin, R., Nucci, M., Medeiros, F., Saleemuddin, A., Garber, J., Birch, C., Mou, H., Gordon, R., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2091 · Cited by 898
Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E., & Sorosky, J. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5345 · Cited by 882
Menon, U., Gentry-Maharaj, A., Hallett, R., Ryan, A., Burnell, M., Sharma, A., Lewis, S., Davies, S., Philpott, S., Lopes, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70026-9 · Cited by 829
Piek, J. M. J., van Diest, P. J., Zweemer, R. P., Jansen, J. W., Poort‐Keesom, R. J. J., Menko, F. H., Gille, J. J. P., Jongsma, A. P. M., Pals, G., Kenemans, P., et al. (2001) · The Journal of Pathology · doi:10.1002/path.1000 · Cited by 787
Cannistra, S. A., Matulonis, U. A., Penson, R. T., Hambleton, J., Dupont, J., Mackey, H., Douglas, J., Burger, R. A., Armstrong, D., Wenham, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0782 · Cited by 759
Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Lacave, A. J., Wagner, U., Stähle, A., Stuart, G., Kimmig, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0913 · Cited by 754
Katsumata, N., Yasuda, M., Takahashi, F., Isonishi, S., Jobo, T., Aoki, D., Tsuda, H., Sugiyama, T., Kodama, S., Kimura, E., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61157-0 · Cited by 727
Bookman, M. A., Brady, M. F., McGuire, W. P., Harper, P. G., Alberts, D. S., Friedlander, M., Colombo, N., Fowler, J. M., Argenta, P. A., De Geest, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1684 · Cited by 705
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
Pal, T., Permuth‐Wey, J., Betts, J. A., Krischer, J. P., Fiorica, J., Arango, H., LaPolla, J., Hoffman, M., Martino, M. A., Wakeley, K., et al. (2005) · Cancer · doi:10.1002/cncr.21536 · Cited by 691
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Fan, I., Tang, J., Li, S., Zhang, S., Shaw, P. A., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj465 · Cited by 680
Grading Ovarian Serous Carcinoma Using a Two-Tier System
Malpica, A., Deavers, M. T., Lu, K., Bodurka, D. C., Atkinson, E. N., Gershenson, D. M., & Silva, E. G. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200404000-00009 · Cited by 670
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.
ten Bokkel Huinink, W., Gore, M., Carmichael, J., Gordon, A., Malfetano, J., Hudson, I., Broom, C., Scarabelli, C., Davidson, N., Spanczynski, M., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2183 · Cited by 663
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Mendes‐Pereira, A. M., Martin, S. A., Brough, R., McCarthy, A., Taylor, J. R., Kim, J., Waldman, T., Lord, C. J., & Ashworth, A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900041 · Cited by 638
Molecular Cloning of the CA125 Ovarian Cancer Antigen
Yin, B. W. T., & Lloyd, K. O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103554200 · Cited by 617
Muggia, F. M., Braly, P. S., Brady, M. F., Sutton, G., Niemann, T. H., Lentz, S. L., Alvarez, R. D., Kucera, P. R., & Small, J. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.106 · Cited by 601
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Rustin, G. J., van der Burg, M. E., Griffin, C. L., Guthrie, D., Lamont, A., Jayson, G. C., Kristensen, G., Mediola, C., Coens, C., Qian, W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61268-8 · Cited by 599
Bhattacharyya, A., Ear, U. S., Koller, B. H., Weichselbaum, R. R., & Bishop, D. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000276200 · Cited by 583
Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P. A., Volgger, B., Vergote, I., Pignata, S., Ferrero, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7519 · Cited by 575
Pathology and classification of ovarian tumors
Chen, V. W., Ruiz, B., Killeen, J. L., Cot�, T. R., Wu, X. C., Correa, C. N., & Howe, H. L. (2003) · Cancer · doi:10.1002/cncr.11345 · Cited by 506
Tan, D. S. P., Rothermundt, C., Thomas, K., Bancroft, E., Eeles, R., Shanley, S., Ardern-Jones, A., Norman, A., Kaye, S. B., & Gore, M. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1703 · Cited by 469
Early Events in the Pathogenesis of Epithelial Ovarian Cancer
Landen, C. N., Birrer, M. J., & Sood, A. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9970 · Cited by 462
2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer
Stuart, G. C. E., Kitchener, H., Bacon, M., duBois, A., Friedlander, M., Ledermann, J., Marth, C., Thigpen, T., & Trimble, E. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31821b2568 · Cited by 425
Gordon, A. N., Tonda, M., Sun, S., & Rackoff, W. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.07.011 · Cited by 422
Rose, P. G., Blessing, J. A., Mayer, A. R., & Homesley, H. D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.405 · Cited by 386
Zorn, K. K., Bonome, T., Gangi, L., Chandramouli, G. V. R., Awtrey, C. S., Gardner, G. J., Barrett, J. C., Boyd, J., & Birrer, M. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0508 · Cited by 376
Hennessy, B. T. J., Timms, K. M., Carey, M. S., Gutin, A., Meyer, L. A., Flake, D. D., Abkevich, V., Potter, J., Pruss, D., Glenn, P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2997 · Cited by 374
Histopathologic Grading of Ovarian Carcinoma: A Review and Proposal
Silverberg, S. G. (2000) · International Journal of Gynecological Pathology · doi:10.1097/00004347-200001000-00003 · Cited by 351
Chi, D. S., McCaughty, K., Diaz, J. P., Huh, J., Schwabenbauer, S., Hummer, A. J., Venkatraman, E. S., Aghajanian, C., Sonoda, Y., Abu‐Rustum, N. R., et al. (2006) · Cancer · doi:10.1002/cncr.21845 · Cited by 350
Mucinous Epithelial Ovarian Cancer: A Separate Entity Requiring Specific Treatment
Hess, V., A'Hern, R., Nasiri, N., King, D. M., Blake, P. R., Barton, D. P. J., Shepherd, J. H., Ind, T., Bridges, J., Harrington, K., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.078 · Cited by 333
Chetrit, A., Hirsh-Yechezkel, G., Ben-David, Y., Lubin, F., Friedman, E., & Sadetzki, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6905 · Cited by 323
Selvakumaran, M., Pisarcik, D., Bao, R., Yeung, A. T., & Hamilton, T. C. (2003) · PubMed · Cited by 317
Moore, R. G., Miller, M. C., Disilvestro, P., Landrum, L. M., Gajewski, W., Ball, J. J., & Skates, S. J. (2011) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e318224fce2 · Cited by 308
Cheng, W., Liu, J., Yoshida, H., Rosen, D., & Naora, H. (2005) · Nature Medicine · doi:10.1038/nm1230 · Cited by 305
Biomarkers to predict the clinical efficacy of bevacizumab in cancer
Jubb, A. M., & Harris, A. L. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70232-1 · Cited by 295
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
Gershenson, D. M., Sun, C. C., Bodurka, D., Coleman, R. L., Lu, K. H., Sood, A. K., Deavers, M., Malpica, A. L., & Kavanagh, J. J. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.03.001 · Cited by 291
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
Press, J. Z., De Luca, A., Boyd, N., Young, S., Troussard, A., Ridge, Y., Kaurah, P., Kalloger, S. E., Blood, K. A., Smith, M., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-17 · Cited by 287
Histologic Subtypes of Ovarian Carcinoma: An Overview
Soslow, R. A. (2008) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e31815ea812 · Cited by 258
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum
Schmeler, K. M., Sun, C. C., Bodurka, D. C., T. Deavers, M., Malpica, A., Coleman, R. L., Ramirez, P. T., & Gershenson, D. M. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.11.013 · Cited by 245
Markman, M., Blessing, J., Rubin, S. C., Connor, J., Hanjani, P., & Waggoner, S. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.10.036 · Cited by 237
Effectiveness of a Multivariate Index Assay in the Preoperative Assessment of Ovarian Tumors
Ueland, F. R., Desimone, C. P., Seamon, L. G., Miller, R. A., Goodrich, S., Podzielinski, I., Sokoll, L., Smith, A., van Nagell, J. R., & Zhang, Z. (2011) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31821b5118 · Cited by 231
History of the FIGO cancer staging system
Odicino, F., Pecorelli, S., Zigliani, L., & Creasman, W. T. (2008) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2007.11.004 · Cited by 169
Itamochi, H., Kigawa, J., Sugiyama, T., Kikuchi, Y., Suzuki, M., & Terakawa, N. (2002) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(02)02040-9 · Cited by 155
Ahmed, A. A., Lü, Z., Jennings, N. B., Etemadmoghadam, D., Capalbo, L., Jacamo, R. O., Barbosa‐Morais, N. L., Le, X., Vivas‐Mejía, P. E., Lopez‐Berestein, G., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.018 · Cited by 152
Self-citationCharacterization of Active Mitogen-Activated Protein Kinase in Ovarian Serous Carcinomas
Hsu, C., Bristow, R. E., Cha, M. S., Wang, B. G., Ho, C., Kurman, R. J., Wang, T., & Shih, I. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0893 · Cited by 148
Friedlander, M. L., Millward, M., Bell, D., Bugat, R., Harnett, P. R., Moreno, J. A., Campbell, L., Varette, C., Ripoche, V., & Kayitalire, L. (1998) · Annals of Oncology · doi:10.1023/a:1008469212268 · Cited by 137
Malander, S., Rambech, E., Kristoffersson, U., Halvarsson, B., Ridderheim, M., Borg, Å., & Nilbert, M. C. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.10.029 · Cited by 126
González-Martı́n, A., Calvo, E., Bover, I., Rubio, M. J., Arcusa, À., Casado, A., Ojeda, B., Balañá, C., Martínez, E. H., Herrero, A., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi147 · Cited by 117
Genetic Analysis of the Early Natural History of Epithelial Ovarian Carcinoma
Pothuri, B., Leitão, M. M., Levine, D. A., Viale, A. J., Olshen, A. B., Arroyo, C. D., Bogomolniy, F., Olvera, N., Lin, O., Soslow, R. A., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010358 · Cited by 113
Huang, J., Zhang, L., Greshock, J. D., Colligon, T. A., Wang, Y., Ward, R., Katsaros, D., Lassus, H. J., Bützow, R. C., Godwin, A. K., et al. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20883 · Cited by 106
CA 125 and the detection of recurrent ovarian cancer
Bast, R. C. (2010) · Cancer · doi:10.1002/cncr.25203 · Cited by 73
Self-citationHirashima, Y., Yamada, Y., Tateishi, U., Kato, K., Miyake, M., Horita, Y., Akiyoshi, K., Takashima, A., Okita, N. T., Takahari, D., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26282 · Cited by 67
Reed, E., Yu, J., Davies, A., Gannon, J., & Armentrout, S. L. (2003) · PubMed · Cited by 65
Personalizing Therapy for Ovarian Cancer: BRCAness and Beyond
Bast, R. C., & Mills, G. B. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.5791 · Cited by 62
Self-citationModulating Microtubule Stability Enhances the Cytotoxic Response of Cancer Cells to Paclitaxel
Ahmed, A. A., Wang, X., Lü, Z., Goldsmith, J., Le, X., Grandjean, G. V., Bartholomeusz, G. A., Broom, B. M., & Bast, R. C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0025 · Cited by 56
Self-citationMore than a biomarker: CA125 may contribute to ovarian cancer pathogenesis
Bast, R. C., & Spriggs, D. R. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.04.032 · Cited by 55
Self-citationBerkenblit, A., Seiden, M. V., Matulonis, U. A., Penson, R. T., Krasner, C. N., Roche, M. R., Mezzetti, L., Atkinson, T., & Cannistra, S. A. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.08.028 · Cited by 49
Minireview: Animal Models and Mechanisms of Ovarian Cancer Development
Mullany, L. K., & Richards, J. S. (2012) · Endocrinology · doi:10.1210/en.2011-2121 · Cited by 44
Mehta, S., Hughes, N. P., Buffa, F. M., Li, S., Adams, R. F., Adwani, A., Taylor, N. J., Levitt, N. C., Padhani, A. R., Makris, A., et al. (2011) · JNCI Monographs · doi:10.1093/jncimonographs/lgr027 · Cited by 43
What have we learned from ICON1 and ACTION?
Colombo, N., & Pecorelli, S. (2003) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2003.13366.x · Cited by 35
Dissecting “PI3Kness”: The Complexity of Personalized Therapy for Ovarian Cancer
Bast, R. C., & Mills, G. B. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0323 · Cited by 34
Self-citationA new standard combination for recurrent ovarian cancer?
Bast, R. C., & Markman, M. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.152 · Cited by 11
Self-citation
Cited by
Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
du Bois, A., Floquet, A., Kim, J.-W., Rau, J., del Campo, J. M., Friedlander, M., Pignata, S., Fujiwara, K., Vergote, I., Colombo, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7348 · Cited by 328
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease
Wilson, M. K., Pujade-Lauraine, E., Aoki, D., Mirza, M. R., Lorusso, D., Oza, A. M., du Bois, A., Vergote, I., Reuss, A., Bacon, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw663 · Cited by 289
Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors
Weiss, J. M., Davies, L. C., Karwan, M., Ileva, L., Ozaki, M. K., Cheng, R. Y. S., Ridnour, L. A., Annunziata, C. M., Wink, D. A., & McVicar, D. W. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99169 · Cited by 267
Ovarian cancer relapse: From the latest scientific evidence to the best practice
Luvero, D., Plotti, F., Aloisia, A., Montera, R., Terranova, C., Nardone, C. D. C., Scaletta, G., Lopez, S., Miranda, A., Capriglione, S., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.014 · Cited by 68
Endometriosis and ovarian cancer
Králíčková, M. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i5.800 · Cited by 27
Metadata
- Authors
- Romero, I., & Bast, R. C.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2012-03-13
- Volume
- 153
- Issue
- 4
- Pages
- 1593-1602
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2062006818
- Cited by
- 286
- References
- 83
- FWCI
- 33.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.